Main > ONCOLOGY (**) > Lung>NSCLC>Non-Squamous>MET or R*** > Treatment > CN. B. PD-1 Binding MAb Injection+

---

CN. B. PD-1 Binding MAb Injection+'s subsections
(*) CN Approval Date: 2021. 06.23.
Company
Generic Name: TislelizuMAb
MAb: Monoclonal Anti Body
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 5
Patent>UpDate: 2021. 06.22.
PD: Programmed Death
PR Web-Site
Product Web-Site

CN. B. PD-1 Binding MAb Injection+'s products
This section has no products